SAN FRANCISCO and TAIPEI, Taiwan, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Acepodia, a biotechnology company developing novel off-the-shelf cell therapies against solid-tumor and hematologic cancers, today announced that Howard Li, Ph.D., Preclinical Research Scientist, will present a late-breaking virtual poster at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting.

Acepodia will participate in live virtual Q&A sessions regarding its poster presentation on November 12 and November 14, 2020. Details on the presentation and virtual Q&A sessions is below.

Presentation Details

Presentation Title: A potent and off-the-shelf oNK cell therapy product targets HER2+ cancer cells and resists suppressive tumor microenvironmentPresenter: Howard Li, Ph.D., Preclinical Research ScientistRegistration link: https://bit.ly/34hiEvH

Q&A Details

Session 1 Date and Time: November 12, 2020 at 3:50 p.m. – 4:20 p.m. ESTSession 2 Date and Time: November 14, 2020 at 1:00 p.m. – 1:30 p.m. EST        Additional information on the ACE1702 study is available at clinicaltrials.gov (NCT04319757)